At a practical level, diagnostic screening for MYB or MYBL1 alteration often occurs at the level of relevant fusion detection, and the current WHO classification for Diffuse astrocytoma, MYB- or MYBL1-altered, emphasizes either the identification of a rearrangement involving these genes, or a DNA methylation profile aligned with diffuse astrocytoma, MYB- or MYBL1-altered, as important diagnostic criteria of these tumors [1]. This evidence concerns the gene MYBL1 and diffuse astrocytoma.